Oral Administration of F-18 FDG to Evaluate a Single Pulmonary Nodule by Positron Emission Tomography in a Patient with Poor Intravenous Access

Clinical Nuclear Medicine

Volumn 28, Issue 7, 2003, Pages 541-544

  Franc, Benjamin ^b   Carlisle, Marie R ^a   Segall, George ^b  

^a Nuclear Medicine Service   (United States)

^b NONE

Author keywords

Fluorodeoxyglucose; Positron emission tomography; Pulmonary nodule

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CANCER; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NODULE; POSITRON EMISSION TOMOGRAPHY; VASCULAR ACCESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGESTIVE SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; LUNG COIN LESION; LUNG TUMOR; METABOLISM; METHODOLOGY; MOUTH; ORAL DRUG ADMINISTRATION; SCINTISCANNING; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AGED; COIN LESION, PULMONARY; DIGESTIVE SYSTEM; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MOUTH; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141499170     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200307000-00001     Document Type: Article

References (8)

1. Gupta NC, Maloof J, Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:6 943, 1996.
2. Fletcher JW: PET scanning and the solitary pulmonary nodule. Semin Thorac Cardiovasc Surg 14:268, 2002.
3. Gould MK, Lillington GA: Strategy and cost in investigating solitary pulmonary nodules. Thorax 53(Suppl 2):S32, 1998.
4. Alibazoglu H, Megremis D, Ali A, et al: Injection artifact on FDG PET imaging. Clin Nucl Med 23:264, 1998.
5. Deslauriers J, Gregoire J: Clinical and surgical staging of non-small cell lung cancer. Chest 117:96S, 2000.
6. Higashi T, Fisher SJ, Nakada K, et al: Is enteral administration of fluorine-18-fluorodeoxyglucoase (F-18 FDG) a palatable alternative to IV injection? Pre-clinical evaluation in normal rodents. Nucl Med Biol 29:363, 2002.
7. Masud M, Yamaguchi K, Rikimaru H, et al: Evaluation of resting brain conditions measured by two different methods (i.v. and oral administration) with 18F-FDG-PET. Ann Nucl Med 15:69, 2001.
8. Martinez ZA, Colgan M, Baxter LR Jr, et al: Oral 18F-fluoro-2-deoxyglucose for primate PET studies without behavioral restraint: demonstration of principle. Am J Primatol 42:215, 1997.